GILEAD SCIENCES, INC. is 5.3x more valuable than BIOGEN INC. by market capitalization ($151.05 B vs $28.68 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | GILD | BIIB |
|---|---|---|
| Market cap | $151.05 B | $28.68 B |
| US-listed rank | #99 | #476 |
| Revenue (latest FY) | $29.44B | $9.89B |
| Net income (latest FY) | $8.51B | $1.29B |
| Net margin | 28.9% | 13.1% |
| P/E (trailing FY) | 17.7 | 22.2 |
| SEC filings | 981 | 2,690 |
GILEAD SCIENCES, INC. is 5.3x more valuable than BIOGEN INC. by market capitalization ($151.05 B vs $28.68 B).
In their latest fiscal years, GILEAD SCIENCES, INC. reported $29.44B in revenue while BIOGEN INC. reported $9.89B.
Full pages: GILEAD SCIENCES, INC. and BIOGEN INC., or browse the full rankings.